Corteva Inc. Common Stock vs Quest Diagnostics Inc — how do they compare? Corteva Inc. Common Stock trades at $13.19 (market cap $9.17B), while Quest Diagnostics Inc trades at $230.57 (market cap $25.48B). The key difference: Quest Diagnostics Inc is far larger — about 2.8× Corteva Inc. Common Stock's market cap, and Corteva Inc. Common Stock pays the higher dividend (5.24%). Which is the better fit depends on your goals — on Pluang, investors hold Corteva Inc. Common Stock for 0 Days and Quest Diagnostics Inc for 56 Days on average.
| CTVA | DGX | |
|---|---|---|
Market Cap | $9.17B | $25.48B |
Volume | 35,183,471 | 941,866 |
Sector | Basic Materials | Health |
52-Week High | $90.51 | $247.45 |
52-Week Low | $11.92 | $173.49 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $11.68B | $31.23B |
Dividend Yield | 5.24% | 1.49% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Corteva provides seeds, crop protection products, and digital tools for agriculture. Its products are used by farmers to manage crop production and protect yields.
Read more on CTVA →Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →